Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 6/20 | 0.48 |
| ▸ | DRD3 | P35462 | 4/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | KDM5A | P29375 | 1/20 | 0.39 |
| ▸ | KDM7A | Q6ZMT4 | 1/20 | 0.39 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.39 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.39 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 3/20 | 0.38 |
| ▸ | HTR1A | P08908 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9409600 | 1.00 | DRD2 (0.48) | DRD2DRD3HPGDALDH1A1KDM5A | |
| SCHEMBL6410297 | 1.00 | DRD2 (0.48) | DRD2DRD3HPGDALDH1A1KDM5A | |
| SCHEMBL11687711 | 0.86 | DRD2 (0.50) | DRD2DRD3HPGDALDH1A1ATM | |
| SCHEMBL11683857 | 0.81 | DRD2 (0.47) | DRD2DRD3HPGDALDH1A1KDM5A | |
| SCHEMBL15788648 | 0.81 | DRD2 (0.43) | DRD2DRD3HPGDALDH1A1ATM | |
| SCHEMBL6417470 | 0.81 | DRD2 (0.43) | DRD2DRD3HPGDALDH1A1ATM | |
| SCHEMBL225429 | 0.81 | DRD2 (0.47) | DRD2DRD3HPGDALDH1A1ATM | |
| SCHEMBL225428 | 0.81 | DRD2 (0.47) | DRD2DRD3HPGDALDH1A1ATM | |
| SCHEMBL6417467 | 0.81 | DRD2 (0.43) | DRD2DRD3HPGDALDH1A1ATM | |
| SCHEMBL16556614 | 0.81 | DRD2 (0.47) | DRD2DRD3HPGDALDH1A1ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050065140-A1 | Serotonine reuptake inhibitor | SUMITOMO PHARMACEUTICALS COMPANY LIMITED (JP) | 2005-03-24 | — | — | US | disclosed |
| EP-1466901-A1 | SEROTONINE REUPTAKE INHIBITOR | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2004-10-13 | — | — | EP | disclosed |
| CN-1064362-C | Pyrimido [5,4-D] pyrimidines, medicaments containing these compounds, their use and process for their production | THOMAE GMBH DR K (DE) | 2001-04-11 | — | — | CN | disclosed |
| CN-1047778-C | Pyrimido [5-4-d] pyrimidines, drugs containing these compounds, their use and process for preparing them | THOMAE GMBH DR K (DE) | 1999-12-29 | — | — | CN | disclosed |
| CN-1212694-A | Pyrimido [5,4-D] pyrimidines, medicaments containing these compounds, their use and process for their production | THOMAE GMBH DR K (DE) | 1999-03-31 | — | — | CN | disclosed |
| US-5821240-A | ENZYME INHIBITORS, SIGNAL INHIBITORS FOR ANTIINFLAMMATORY AGENTS, ANTICARCINOGENIC AGENTS, ANTITUMOR AGENTS AND HORMONE INHIBITORS | DR. KARL THOMAE GMBH (DE) | 1998-10-13 | — | — | US | disclosed |
| US-5707989-A | ANTITUMOR AGENTS, INHIBITING SIGNAL TRANSDUCTION MEDIATED BY TYROSINE KINASES | DR. KARL THOMAE GMBH (DE) | 1998-01-13 | — | — | US | disclosed |
| CN-1157619-A | Pyrimido [5-4-d] pyrimidines, drugs containing these compounds, their use and process for preparing them | THOMAE GMBH DR K (DE) | 1997-08-20 | — | — | CN | disclosed |
| CN-1094035-A | Carboxylic acid derivative contains pharmaceutical composition of these compounds and preparation method thereof | THOMAE GMBH DR K (DE) | 1994-10-26 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065140-A1 | Serotonine reuptake inhibitor | HTR1A, SLC6A4, SLC6A2 | DRD2 79/4885DRD3 194/4885HPGD 853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.